General Information of Drug Combination (ID: DCMBERR)

Drug Combination Name
CHS-828 Eltanexor oral
Indication
Disease Entry Status REF
Ewing sarcoma Investigative [1]
Component Drugs CHS-828   DMTV4L7 Eltanexor oral   DM7CLEZ
Small molecular drug N.A.
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: TC-71
Zero Interaction Potency (ZIP) Score: 10.498
Bliss Independence Score: 7.793
Loewe Additivity Score: 4.541
LHighest Single Agent (HSA) Score: 6.766

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of CHS-828
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [2]
CHS-828 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Nicotinamide phosphoribosyltransferase (NAMPT) TTD1WIG NAMPT_HUMAN Inhibitor [2]
------------------------------------------------------------------------------------
Indication(s) of Eltanexor oral
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 1/2 [3]
Myelodysplastic syndrome 2A37 Phase 1/2 [3]
Prostate cancer 2C82.0 Phase 1/2 [3]
Eltanexor oral Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Exportin-1 (XPO1) TTCJUR4 XPO1_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------

References

1 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
2 Anticancer agent CHS-828 inhibits cellular synthesis of NAD. Biochem Biophys Res Commun. 2008 Mar 21;367(4):799-804.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)